What is ARTMS?
ARTMS is at the forefront of medical isotope production, focusing on QUANTM targets that empower local cyclotrons to generate critical isotopes for Oncology and Cardiology. Their innovative approach circumvents the need for centralized isotope production, thereby ensuring a more reliable and timely supply of essential isotopes like Gallium-68. The company's mission is to advance human health by leading the medical isotope sector, offering solutions that seamlessly integrate with existing cyclotron infrastructure. ARTMS actively partners with pharmaceutical innovators and distributors to address the escalating demand for vital nuclear medicine products.
How much funding has ARTMS raised?
ARTMS has raised a total of $22M across 2 funding rounds:
Private Equity
$3M
Series A
$19M
Private Equity (2017): $3M with participation from GF Securities and Quark Venture Inc.
Series A (2020): $19M led by Deerfield Communications Inc, GF Securities Co. Ltd, and Quark Venture
Key Investors in ARTMS
GF Securities
GF Securities is a financial services company that likely provides capital and strategic guidance to companies within its investment portfolio.
Quark Venture Inc.
Quark Venture Inc. is a venture capital firm specializing in equity financing for innovative biotechnology companies, focusing on breakthrough technology platforms and aiming to enhance their value through strategic support.
Deerfield Communications Inc
Deerfield Communications Inc. is an entity that has participated in the funding round, though its specific investment focus is not detailed.
What's next for ARTMS?
The substantial enterprise-level capital infusion positions ARTMS for accelerated growth and expanded market penetration. This strategic backing is expected to fuel further research and development into novel isotope production technologies and enhance their manufacturing capabilities. ARTMS is poised to solidify its leadership in the medical isotope supply chain, potentially driving advancements in diagnostic and therapeutic applications within nuclear medicine. The company's focus on localized production addresses critical supply chain vulnerabilities, making it a key player in ensuring consistent access to life-saving medical isotopes.
See full ARTMS company page
